In this competitive AlA for determining concentrations of human C5a in biological fluids and in buffers, labeled C5a and sample are allowed to compete for binding to a limited amount of goat antibody to human C5a in solution. Free and bound tracer are then separated by a second antibody (rabbit anti-goat IgG) immobilized on paramagnetic particles. Total Incubation time for this assay is 70 mi Sensitivity, precision, and analytical recovery of this assay compare well with those of a reference method.
C5a standard.s. Purified C5a antigen was diluted with sodium phosphate buffer (0.1 mol/L, pH 8.0) containing 2 g of gelatin, 1 g of protamine sulfate, and 1 g of sodium azide per liter to give concentrations of 400, 160, 50, 25, and 10 pgfL. Diluent buffer was used as the 0 pg/L standard. We assayed these standards with the C5a desArg RIA kit and adjusted them accordingly if the assayed value of any standard differed by >10% from the target value. All standards were stored in plastic vials at 4-8 #{176}C.
lasILabeled C5a tracer. We prepared 2.5 pg of C5a per 3-mL batth-size tracer by Bio-Rad's radioiodination method, using Enzymobeads reagent. Free iodide was separated by passing through a 1 x 15 cm column of Sephadex G-25 (fine) gel. Because C5a itself bound significantly to the column, we mixed protamine sulfate with the tracer as protein carrier before the tracer was applied to the column.
Goat anti-human C5a antibody (first antibody). We diluted the IgG fraction of the antiserum with sodium phosphate buffer (50 mmol/L, pH 7.4) containing 8.7 g of NaCl, 2.5 g of gelatin, and 1 g of sodium azide per liter. To determine the proper dilution of the antibody in the assay, we determined which dilutions produced a standard curve having a slope of -1.1 (± 0.1) and EDso of 50 pg/L (± 2 ,ug/L) on a plot of logit BIB0 vs log dose. ED is the concentration of C5a causing a displacement of 50% of tracer bound at zero concentration of C5a, designated B0.
Rabbit anti-human C5a PMP. We immobilized rabbit antibodies to goat IgG on the PMP solid phase by the glutaraldehyde method (7). We determined the concentration of these particles to be used in the assay system by maximizing B0/T, B0 being the maximum tracer bound in the absence of C5a, and Tbeing the total tracer in the tube. In practice, this second antibody is always used in large excessover the first antibody, to shorten the second incubation time.
Sample-precipitating agent. We dissolved Rivanol in distilled water to give a concentration of 12.5 gIL, a concentration we selected by comparing a series of concentrations of Rivanol in the recovery study of a serum sample of known C5a content. The unique feature of Rivanol as the precipitating agent is that it precipitates most serum proteins except IgG (8); thus it does not precipitate antibody during the assay's incubation.
Coating buffer. This is sodium phosphate buffer (50 mmol/L, pH 7.4) containing 2.5 g of gelatin, 0.25 g of protamine sulfate, and 1 g of sodium azide per liter. It was used for coating the test tube before the sample was introduced. We found that protamine sulfate allowed all the C5a molecules in the sample to participate in the immunoreaction by preventing C5a from binding to the test tube surface.
Wash buffer. This is sodium phosphate buffer (10 mmol/L, Assay procedure. Pipet 504 of coating buffer into each tube and vortex-mix well to coat the tubes. Then add 504 of standard or sample supernate to the appropriate tubes followed by 504 each of tracer and first antibody, in that order. To the nonspecific binding (NSB) tube, add 504 of zero standard instead of the first antibody. Vortex-mix, incubate for 1 h at room temperature, and then add 5004 of the second-antibody solid-phase particle suspension to all except the total-count tubes. Vortex-mix again and incubate for 10 mm at room temperature. Terminate the incubation by separating the solid phase by means of a MAGIC' magnetic-separation unit.
Wash the particles twice with 500-4 portions of the wash buffer, then count the radioactivity bound on the solid phase for 1 mm (we used a "Corning 4000" multi-well gamma counter, which has a software program to generate a logitlog standard curve from which sample values are read).
Results
Cross reactivity. C5a in serum is present in microgram per liter concentrations, whereas C5 is in milligram per liter concentrations. C3a is known to have a marked homology with C5a in amino acid sequence (4). Both CS and C3a, including its precursor C3, could thus substantially interfere in the C5a assay if they crossreact with the anti-human C5a antibody. To determine whether sample pretreatment would be necessary to eliminate C5, C3, and C3a from serum samples, we added increasing amounts of C5 and C3 to the assay system and observed their inhibition of the binding of C5a tracer to the antibody. The inhibition curves "MAGIC" is the trademark of Ciba-Corning Diagnostics' immunoasaayproducts in which magnetic-separation technology is used. for C5a, C5, and C3 (Figure 1) indicate that C5 at its normal concentration (80 mg/L) in serum will interfere significantly in the C5a assay, whereas there is no or insignificant interference from C3, even if all of C3 is converted to C3a (up to 7 mg/L). The potential interference from C5 thus makes it necessary to treat samples prior to assay.
C5a standard curve. We compared our standard curve with Amersham's and found them almost identical on a logit-log plot (Figure 2 ). C5a tracers with up to 20% differences in specific activities gave no significant difference in slope and ED of the standard curve when two curves were normalized by a log-logit transformation.
Correlation with Amersham's method. We ran both methods in parallel with a mixed population of C5a samples composed of regular and diluted serum samples as well as samples in non-serum-based buffer. Results by the two methods correlated reasonably well over the total population of samples but showed a significant bias between them ( Figure 3A) . However, when we compared the two methods within each different sample population, it became apparent that they correlated the best with both regular serum and non-serum samples ( Figure SB) . All the bias came from the diluted serum samples (Figure 3C ). Amersham's kit generally gave 10% higher values than our method.
Assay sensitivity. Basically this part of our study was to show how well this assay can distinguish between two samples that have only 10% difference in C5a concentration. Because it is hard to have a true zero serum pool that could be used as a sample diluent, we diluted instead of serumbasedC5a an aqueous sample of known value with barbit.alJ gelatin buffer in such a way asto decrease by 10% the C5a concentration at each step until the final sample contained about a third of the C5a of the starting sample. We then assayed these samples. Except for one sample, all of them gave values that were 90-110% of the expected ( Table 1) . The one potential overlapping value was between the 167 pg/L and 150 pg/L samples. Each value Is the mean ofduplicate samples (allCVs<10%). parallel with a matching (nonheat-stressed) kit as a control. The treated kit was just as stable as the control (Table 2) . Carrier protein. Two unique phenomena prompted additional study. (a) the loss of C5a tracer total radioactivity in PBS/gelatin buffer during storage, and (b) non-elution of tracer from the Sephadex G-25 column unless a particular carrier protein is included ( Figure 5 ).
Precision.
The effectiveness of three proteins (BSA, gelatin, and profamine sulfate) in keeping C5a in solution were in the order protanhine sulfate > BSA> gelatin. Use of protamine sulfate also gave the best analytical recovery of C5a in the assay.
Discussion
Results by the method presented compare well with those by the Amersham method. Use of paramagnetic particles to separate bound from free tracer saves assay time.
The nonspecific binding of this method is less than 10% of the total count at B0. This makes unnecessary subtraction of nonspecific binding in the calculation of each individual sample. The 1-h incubation with first antibody in our method is 2 h shorter than in Amersham's method. This might be ascribed to either a better first antibody used in our method or a more efficient second antibody solid phase to pick up signals.
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